These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 18627334)
1. Docetaxel in the management of prostate cancer: current standard of care and future directions. De Dosso S; Berthold DR Expert Opin Pharmacother; 2008 Aug; 9(11):1969-79. PubMed ID: 18627334 [TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
3. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Logothetis CJ Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic chemotherapy for prostate cancer: Who and when? Moss RA; Petrylak DP Curr Treat Options Oncol; 2006 Sep; 7(5):370-7. PubMed ID: 16904054 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials. Qi WX; Fu S; Zhang Q; Guo XM J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160 [TBL] [Abstract][Full Text] [Related]
14. Practical guide to the use of chemotherapy in castration resistant prostate cancer. Petrylak DP Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728 [TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Armstrong AJ; George DJ Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005 [TBL] [Abstract][Full Text] [Related]
16. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Antonarakis ES; Armstrong AJ Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):192-205. PubMed ID: 21577234 [TBL] [Abstract][Full Text] [Related]
17. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099 [TBL] [Abstract][Full Text] [Related]
18. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for hormone-refractory prostate cancer. Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249 [TBL] [Abstract][Full Text] [Related]